These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 24918318)

  • 1. Skin reactions during anti-TNFα therapy for pediatric inflammatory bowel disease: a 2-year prospective study.
    Mälkönen T; Wikström A; Heiskanen K; Merras-Salmio L; Mustonen H; Sipponen T; Kolho KL
    Inflamm Bowel Dis; 2014 Aug; 20(8):1309-15. PubMed ID: 24918318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease.
    Kolho KL; Sipponen T
    Scand J Gastroenterol; 2014 Apr; 49(4):434-41. PubMed ID: 24597837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infliximab-induced skin manifestations in patients with inflammatory bowel disease.
    Hellström AE; Färkkilä M; Kolho KL
    Scand J Gastroenterol; 2016; 51(5):563-71. PubMed ID: 26728295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases.
    Guerra I; Algaba A; Pérez-Calle JL; Chaparro M; Marín-Jiménez I; García-Castellanos R; González-Lama Y; López-Sanromán A; Manceñido N; Martínez-Montiel P; Quintanilla E; Taxonera C; Villafruela M; Romero-Maté A; López-Serrano P; Gisbert JP; Bermejo F
    J Crohns Colitis; 2012 Jun; 6(5):518-23. PubMed ID: 22398059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one-hour infusion of infliximab during maintenance therapy is safe and well tolerated: a prospective cohort study.
    Lee TW; Singh R; Fedorak RN
    Aliment Pharmacol Ther; 2011 Jul; 34(2):181-7. PubMed ID: 21615434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis induced by infliximab in a patient suffering from Crohn's disease.
    Manni E; Barachini P
    Int J Immunopathol Pharmacol; 2009; 22(3):841-4. PubMed ID: 19822070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort.
    Bálint A; Rutka M; Végh Z; Kürti Z; Gecse KB; Banai J; Bene L; Gasztonyi B; Kristóf T; Lakatos L; Miheller P; Palatka K; Patai Á; Salamon Á; Szamosi T; Szepes Z; Tóth GT; Vincze Á; Bor R; Milassin Á; Fábián A; Nagy F; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Lakatos PL; Molnár T; Farkas K
    Expert Opin Drug Saf; 2017 Aug; 16(8):885-890. PubMed ID: 28504555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infliximab therapy in children and adolescents with inflammatory bowel disease.
    Veres G; Baldassano RN; Mamula P
    Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.
    Van Assche G; Vermeire S; Noman M; Amant C; Weyts E; Vleminckx A; Vermeyen MJ; Rutgeerts P
    J Crohns Colitis; 2010 Sep; 4(3):329-33. PubMed ID: 21122522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
    Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
    Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease: impact on infliximab retreatment.
    Fréling E; Peyrin-Biroulet L; Poreaux C; Morali A; Waton J; Schmutz JL; Guéant JL; Barbaud A
    Eur J Gastroenterol Hepatol; 2015 Oct; 27(10):1200-8. PubMed ID: 26181108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are accelerated infliximab infusions safe in patients with inflammatory bowel disease?
    Bhat S; Sharma D; Doherty P; Tham TC; Caddy GR
    Inflamm Bowel Dis; 2010 Nov; 16(11):1922-5. PubMed ID: 20848465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
    Eickstaedt JB; Killpack L; Tung J; Davis D; Hand JL; Tollefson MM
    Pediatr Dermatol; 2017 May; 34(3):253-260. PubMed ID: 28211161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
    Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
    Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of acute adverse events related to infliximab infusions in pediatric patients.
    Lahdenne P; Wikström AM; Aalto K; Kolho KL
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):785-90. PubMed ID: 20535789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of infliximab in pediatric patients with inflammatory bowel disease.
    Serrano MS; Schmidt-Sommerfeld E; Kilbaugh TJ; Brown RF; Udall JN; Mannick EE
    Ann Pharmacother; 2001; 35(7-8):823-8. PubMed ID: 11485127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasiform and pustular eruption induced by infliximab.
    Takahashi H; Hashimoto Y; Ishida-Yamamoto A; Ashida T; Kohgo Y; Iizuka H
    J Dermatol; 2007 Jul; 34(7):468-72. PubMed ID: 17584325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
    Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
    Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.